Chronic Liver Disease Market to Witness Growth by 2032 | Major players- Novo Nordisk A/S, Madrigal Pharmaceuticals, Axcella Therapeutics, 89bio, expected to boost the market

DelveInsight's "Chronic Liver Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Liver Disease, historical and forecasted epidemiology as well as the Chronic Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chronic Liver Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Liver Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chronic Liver Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Liver Disease market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Chronic Liver Disease: An Overview
Chronic liver disease refers to conditions that lead to long-term damage and impairment of the liver's function. There are various causes of chronic liver disease, including viral infections (such as hepatitis B and C), excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), autoimmune diseases affecting the liver (like autoimmune hepatitis), genetic disorders (such as hemochromatosis or Wilson's disease), and certain medications or toxins.

Liver Damage and Progression: Chronic liver disease is characterized by ongoing inflammation and damage to liver cells over an extended period. This damage can lead to the formation of scar tissue (fibrosis) and ultimately progress to cirrhosis, a condition in which the liver becomes severely scarred and its function is impaired.
Symptoms: In the early stages, chronic liver disease may not cause noticeable symptoms. As the disease progresses, symptoms may include fatigue, weakness, jaundice (yellowing of the skin and eyes), abdominal swelling or ascites, easy bruising or bleeding, itching, loss of appetite, nausea, and weight loss.
Complications: Advanced chronic liver disease, especially cirrhosis, can lead to various complications, such as portal hypertension (increased pressure in the veins that supply the liver), varices (enlarged blood vessels in the esophagus or stomach that can bleed), hepatic encephalopathy (confusion and altered mental function due to liver failure), increased risk of infections, liver cancer, and end-stage liver failure necessitating liver transplantation.
Diagnosis: Diagnosis of chronic liver disease involves a combination of medical history, physical examination, blood tests to assess liver function and detect markers of liver damage, imaging studies (such as ultrasound, CT scan, or MRI), and sometimes liver biopsy to evaluate the extent of liver damage and rule out other conditions.
Treatment and Management: The approach to managing chronic liver disease depends on the underlying cause and the stage of liver damage. Treatment may involve lifestyle modifications (such as abstinence from alcohol, weight loss in the case of NAFLD), medications to manage specific conditions (antiviral therapy for hepatitis B or C), addressing complications, dietary changes, and in some cases, liver transplantation for end-stage liver disease.
Prevention: Preventive measures include vaccination against hepatitis viruses (especially for hepatitis B), practicing safe sex, avoiding excessive alcohol consumption, maintaining a healthy diet and weight, and promptly seeking medical care for conditions that could affect the liver.
Early detection and intervention are crucial in managing chronic liver disease to prevent or slow down the progression of liver damage and reduce the risk of complications. Regular monitoring by healthcare providers, adherence to treatment plans, and lifestyle modifications can significantly impact the course of the disease and improve outcomes for individuals with chronic liver disease
Learn more about Chronic Liver Disease, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Chronic Liver Disease Market

The management of patients with Chronic Liver Disease depends on the stage of the liver disease. Liver fibrosis and cirrhosis result from underlying conditions like NASH, ALD, CHB, CHC, and others which progress to a stage of severity that becomes chronic due to the lack of standard treatment.

As per the guidelines from the American Liver Foundation, without any branded approvals, management of underlying comorbidity that is central to treating NASH and related fibrosis is of utmost importance. Various off-label therapies are used to manage Chronic Liver Disease complications, such as vitamin E (an antioxidant), insulin sensitizers (e.g., metformin, pioglitazone), anti-hyperlipidemic agents (e.g., gemfibrozil), pentoxifylline, and UDCA.

According to DelveInsight, the Chronic Liver Disease market is expected to witness considerable changes in the 7MM during the study period 2019-2032.

Request a sample and discover more about the report offerings at: https://www.delveinsight.com/sample-request/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Chronic Liver Disease Epidemiology Insights
According to Ginès et al. (2016), the prevalence of increased liver stiffness in the general adult population without previously known liver diseases is high (between 5.6% and 7.5%). The prevalence among individuals with risk factors is much higher (between 18% and 27%), which suggests an alarmingly high prevalence of chronic liver diseases in the general population.
According to Axley et al. (2018), the fibrosis stages range from F0 to F4. Advanced liver fibrosis is an important predictor of liver disease progression and mortality, and current guidelines recommend screening for complications of cirrhosis once patients develop F3 fibrosis.
According to Ginès et al. (2016), studies have shown that 6-7% of adults without known liver disease have liver fibrosis, mostly associated with non-alcoholic fatty liver disease.


Explore more about Chronic Liver Disease Epidemiology at: https://www.delveinsight.com/report-store/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Liver Disease Drugs Chapters

Chronic Liver Disease Drug Chapters
Emerging Drugs
While several late-staged and early-staged therapeutics are under development, the pharmaceutical product pipeline of Chronic Liver Disease is prolific. It includes leading pharma players in the pursuit of cracking the code in the protracted hepatology space.
Semaglutide: Novo Nordisk
Semaglutide is a selective GLP-1 receptor agonist given once daily, subcutaneously, for the treatment of non-alcoholic steatohepatitis (NASH). Based on studies, the development of Semaglutide in NASH is very much on track. It is currently in Phase III of its clinical development with a promise for closer to a solution that can be a potential launch in the hepatology space during the forecast period.
Resmetirom (formerly MGL-3196): Madrigal Pharmaceuticals
Madrigal's main attraction was its lead NASH compound, MGL-3196, a once-daily pill for fatty liver disease in-licensed from Roche, Resmetirom (formerly MGL-3196), a Phase III molecule that is a first-in-class, oral, once-daily formulation to target F2 and F3, and F4 stage patients. The company plans to file subpart H-accelerated approval for sooner entry into the market. This filling will be done based on recently published results; later, it will be continued by full NDA submission. Resmetirom also has FTD, which will help shorten the filling period. If all goes as planned, Resmetirom can be a potential launch in the hepatology space during the forecast period.

Chronic Liver Disease Pipeline Development Activities

The Chronic Liver Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Chronic Liver Disease key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Chronic Liver Disease pipeline development activities at: https://www.delveinsight.com/sample-request/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Liver Disease Therapeutics Assessment

Major key companies such as Novo Nordisk A/S, Madrigal Pharmaceuticals, Axcella Therapeutics, 89bio, and others are working proactively in the Chronic Liver Disease Therapeutics market to develop novel therapies which will drive the Chronic Liver Disease treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Chronic Liver Disease Report Key Insights

1. Chronic Liver Disease Patient Population
2. Chronic Liver Disease Market Size and Trends
3. Key Cross Competition in the Chronic Liver Disease Market
4. Chronic Liver Disease Market Dynamics (Key Drivers and Barriers)
5. Chronic Liver Disease Market Opportunities
6. Chronic Liver Disease Therapeutic Approaches
7. Chronic Liver Disease Pipeline Analysis
8. Chronic Liver Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Chronic Liver Disease Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Chronic Liver Disease Competitive Intelligence Analysis
4. Chronic Liver Disease Market Overview at a Glance
5. Chronic Liver Disease Disease Background and Overview
6. Chronic Liver Disease Patient Journey
7. Chronic Liver Disease Epidemiology and Patient Population
8. Chronic Liver Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Liver Disease Unmet Needs
10. Key Endpoints of Chronic Liver Disease Treatment
11. Chronic Liver Disease Marketed Products
12. Chronic Liver Disease Emerging Therapies
13. Chronic Liver Disease Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Liver Disease Market Outlook (7 major markets)
16. Chronic Liver Disease Access and Reimbursement Overview
17. KOL Views on the Chronic Liver Disease Market
18. Chronic Liver Disease Market Drivers
19. Chronic Liver Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Chronic Liver Disease Market report here: https://www.delveinsight.com/report-store/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+91-9650213330
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.